Novavax intends to file for regulatory authorizations for its COVID-19 vaccine in the third quarter and remains on track to reach a manufacturing capacity of 100 million doses per month by the end of the third quarter.
NACDS chair Colleen Lindholz and vice chair Brian Nightengale emphasized pharmacies’ continued role in fostering vaccine confidence and ensuring equitable access to COVID-19 vaccines.